Literature DB >> 25128470

Intranasal nerve growth factor attenuates tau phosphorylation in brain after traumatic brain injury in rats.

Qiushi Lv1, Wenya Lan1, Wenshan Sun1, Ruidong Ye1, Xiaobing Fan1, Minmin Ma1, Qin Yin1, Yongjun Jiang1, Gelin Xu1, Jianwu Dai2, Ruibing Guo3, Xinfeng Liu4.   

Abstract

Traumatic brain injury (TBI) is a considerable cause of mild cognitive impairment and dementia. Intranasal administration of nerve growth factor (NGF) has previously been found to improve cognitive function after TBI, but the mechanism remains unclear. This study aimed to investigate the effects of intranasal NGF on the tau hyperphosphorylation following TBI. A modified Feeney's weight-drop model was used to induce TBI. Rats were randomly divided into control group, TBI group, TBI+NGF group, TBI+PDTC group and TBI+IL-1ra group. Rats in TBI+NGF group were administered with NGF (5 μg/d) for 3d before surgery. Hyperphosphorylated tau protein was remarkable in the peri-contusional cortex area with TBI. Both western blotting and immunostaining results displayed intranasal pretreatment of NGF significantly reduced tau phosphorylation. To evaluate the underlying mechanism, the levels of glycogen synthase kinase 3β (GSK-3β), interleukin-1β (IL-1β), and the DNA binding activity of nuclear factor-κB (NF-κB) were assayed. NGF markedly inhibited GSK-3β. NGF also reduced TBI-induced elevation of IL-1β and NF-κB DNA binding activity. Furthermore, PDTC and IL-1ra were injected to prove a potential signaling pathway among NF-κB, IL-1β and GSK-3β. Taken together, these findings demonstrated that intranasal NGF could effectively attenuate the hyperphosphorylation of tau after TBI, which might involve an integrated signaling pathway related to NF-κB.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  GSK-3β; IL-1β; Intranasal; Nerve growth factor; Tau; Traumatic brain injury

Mesh:

Substances:

Year:  2014        PMID: 25128470     DOI: 10.1016/j.jns.2014.06.037

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

Review 1.  Investigational agents for treatment of traumatic brain injury.

Authors:  Ye Xiong; Yanlu Zhang; Asim Mahmood; Michael Chopp
Journal:  Expert Opin Investig Drugs       Date:  2015-03-01       Impact factor: 6.206

2.  Intranasal Delivery of Collagen-Loaded Neprilysin Clears Beta-Amyloid Plaques in a Transgenic Alzheimer Mouse Model.

Authors:  Christian Humpel
Journal:  Front Aging Neurosci       Date:  2021-04-22       Impact factor: 5.750

Review 3.  Peptides Derived from Growth Factors to Treat Alzheimer's Disease.

Authors:  Suzanne Gascon; Jessica Jann; Chloé Langlois-Blais; Mélanie Plourde; Christine Lavoie; Nathalie Faucheux
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

4.  Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression.

Authors:  Yong-Lin Zhao; Jin-Ning Song; Xu-Dong Ma; Bin-Fei Zhang; Dan-Dong Li; Hong-Gang Pang
Journal:  Neural Regen Res       Date:  2016-06       Impact factor: 5.135

Review 5.  The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer's Disease.

Authors:  Olga N Kokiko-Cochran; Jonathan P Godbout
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

6.  Traumatic Brain Injury Induces Tau Aggregation and Spreading.

Authors:  George Edwards; Jing Zhao; Pramod K Dash; Claudio Soto; Ines Moreno-Gonzalez
Journal:  J Neurotrauma       Date:  2019-08-28       Impact factor: 5.269

Review 7.  Intranasal neprilysin rapidly eliminates amyloid-beta plaques, but causes plaque compensations: the explanation why the amyloid-beta cascade may fail?

Authors:  Christian Humpel
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.